French biotech Abivax suffered its largest intraday decline on record after reporting new data on its lead experimental inflammatory bowel disease drug, which showed cancer cases among patients in the clinical trial. The new data certainly point to regulatory headwinds and raise the risk profile for approval.
Abivax's ABTECT maintenance data showed strong efficacy readout, with both once-daily obefazimod doses meeting the primary endpoint at week 44. Clinical remission rates were 50.8% for the 25 mg dose and 51.3% for the 50 mg dose, versus 10.4% for placebo, implying placebo-adjusted remission rates of about 39% to 40% and highly statistically significant results.
The problem for the stock was not efficacy, but safety optics...
Goldman analyst Esah Hayat pointed out that the market was focused not on efficacy but on cancer cases among patients taking the higher doses of obefazimod:
ABTECT maintenance trial out yday (press release) – "at week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary endpoint, demonstrating placebo-adjusted clinical remission rates of ∆39.3% and ∆40.3%, respectively (25 mg: 50.8%, 50 mg: 51.3% vs placebo 10.4%; p<0.0001)."
Though no new safety signals were observed per the press release, the safety results summary table (below) indicated 8 cases of malignancy, which spooked the market. Note, a number of investors are in this name for the M&A takeout story which could be muddied on this update. Mgmt did host a call on the results in which they did suggest the malignancies observed do align with background rates in UC (e.g. here for basal cell carcinoma), and weren't considered a new safety signal by monitoring committees. Wonder if this becomes a Fenebrutinib-like situation where market goes negative on headline safety imbalance, those are explained away as non-treatment linked at a detailed presentation and docs come out in support of the drug, and we see a re-rating.
The pushback this morning is that pharma BD teams are now unlikely to take on the risk here – and that this is now a solid solo story with fair value likely still in the $100+ region, and so there is upside out of today's levels but in fairness, not many (visible) catalysts to realise it – CD data in mid-27. And we are in a challenging biotech tape as it is, with SMMT -10% yday on myopic focus around >65 age subgroup, despite mgmt assuring this was due to baseline imbalances (which had been addressed at 2025 ESMO too, no less) and after adjusting for these, PFS HR would've been an in-line 0.69, not 0.88 (note).
In a separate note, Jefferies analysts stated, "The cancer signal complicates matters. Even if it is unrelated noise, we think the overhang will be real, especially considering the absence of other value-inflecting data events over the next year."
They noted that "a reasonable explanation" for the cancer cases was plausible, but "it doesn't seem like an easily dismissed overhang." This prompted the analysts to downgrade the stock from a "Buy" rating to "Hold."
Abivax shares in Paris crashed 31.4%, exceeding the 31.03% drop on June 6, 2016.
All gains for 2026 were wiped out.
Analysts tracked by Bloomberg were overwhelmingly bullish, with 4 "Buy" ratings, 1 "Hold," and 0 "Sells."
"While the malignancy signal cannot be ignored, we view it as a potential labeling overhang rather than evidence of a clear causal safety risk," Stifel analyst Damien Choplain told clients.
CNBC noted, "Abivax has been positioned as a prime takeover target, with unconfirmed rumors that big pharma has its eyes on the clinical-stage biotech led by CEO Marc de Garidel."
The key question now is whether Abivax remains a "prime" takeover target after the cancer overhang complicated what had been a clean M&A story in the rumor mill.
Tyler Durden Tue, 06/02/2026 - 07:45The Trump administration appears to be trying to inject new optimism across the nation's farm belt following the China meeting last month, during which Beijing committed to making billions of dollars of new purchases of U.S. agricultural goods. The White House's latest move is to reduce tariffs on tractors and combines, a policy shift aimed at easing cost pressures on farmers already squeezed by diesel, fertilizer, and machinery costs.
Late Monday, President Trump signed a proclamation slashing tariffs on imported agricultural equipment, including combines and harvesters, from 25% to 15% to lower costs for US farmers and manufacturers.
More color from the White House:
The Proclamation adjusts the tariffs on agricultural equipment, like combines and harvesters, as well as certain other equipment, from 25% to 15%.
The Proclamation also expands the existing category of industrial equipment subject to a 15% tariff to include mobile industrial equipment, like bulldozers and forklifts, when imported from trade deal countries that are entitled to such treatment.
The Proclamation encourages foreign companies to use more U.S. steel and aluminum by allowing them to qualify for a 10% duty rate, if their capital equipment include at least 85% U.S. melted and poured or smelted and cast steel or aluminum by weight.
These tariff changes are temporary, lasting until December 31, 2027, to spur near–term investments that will rebuild the Nation's industrial base.
The move is a clear attempt by the Trump administration to spur optimism across the nation's farm belt following China's commitments last month to purchase $17 billion annually in additional U.S. agricultural goods.
The latest reading of the US ag economy via the Purdue University/CME Group Ag Economy Barometer has been fading from a summer 2025 peak as trade wars and, now, the Gulf-related energy shock hurt farmers' incomes.
Trump's directive sent shares of the Japanese agricultural and industrial machinery company Kubota up 5% in Tokyo trading.
Efforts to boost farmer sentiment come ahead of the midterm election cycle, which is gearing up and is only 154 days away.
Tyler Durden Tue, 06/02/2026 - 06:55